Custom VHH nanobody discovery workflows optimized for ELISA capture and detection applications, ensuring high affinity and specificity against your target antigen.
Humanization of camelid-derived nanobodies for ELISA reagent development, reducing immunogenicity while maintaining ELISA binding performance.
High-quality membrane protein production for use as ELISA antigens and screening targets, enabling nanobody selection against challenging cell-surface proteins.
Native VHH antibody library construction from immunized camelids, providing a rich diversity pool for ELISA-optimized nanobody screening and selection.
Nanobody Design for ELISA refers to the rational engineering and selection of single-domain antibody fragments (VHH, also known as nanobodies) derived from camelid heavy-chain-only antibodies, specifically optimized for use as capture or detection reagents in enzyme-linked immunosorbent assay (ELISA) formats. Unlike conventional monoclonal antibodies, nanobodies possess a unique convex paratope structure that can access cryptic epitopes on antigens — including recessed grooves and active sites — that are inaccessible to traditional antibodies.
At Alpha Lifetech Inc., our nanobody design pipeline for ELISA integrates immunization, phage/yeast display library construction, high-throughput screening, affinity maturation, and ELISA-format validation into a seamless end-to-end workflow. The result is a panel of highly specific, thermostable, and chemically robust nanobodies ready for direct integration into sandwich ELISA, competitive ELISA, or multiplex immunoassay systems.
With molecular weights of only ~15 kDa, nanobodies offer exceptional tissue penetration, low batch-to-batch variability, and the ability to be produced in microbial expression systems at scale — making them the reagent of choice for next-generation ELISA kit development across diagnostics, food safety, environmental monitoring, and pharmaceutical quality control.
Picomolar binding affinities enable detection of low-abundance biomarkers in complex biological matrices such as serum, urine, and tissue lysates.
Nanobodies retain full binding activity after exposure to temperatures up to 70°C and can be lyophilized for ambient-temperature shipping — critical for point-of-care ELISA kits.
The convex CDR3 loop of nanobodies penetrates enzyme active sites, viral capsid canyons, and GPCR transmembrane domains — enabling ELISA detection of targets previously considered undruggable.
Nanobodies are efficiently expressed in E. coli and yeast at gram-scale yields, eliminating the cost and complexity of mammalian cell culture for ELISA reagent manufacturing.
Site-specific chemical handles (SpyTag, sortase, azide) enable precise conjugation to HRP, biotin, fluorophores, or magnetic beads for ELISA signal generation without loss of binding activity.
Rational epitope mapping and counter-selection during library screening eliminate cross-reactive clones, delivering ELISA reagents with outstanding selectivity in multiplex formats.
Structural analysis and ELISA epitope mapping to define optimal immunogen format.
Alpaca or llama immunization with validated antigen; serum titer monitoring by ELISA.
Peripheral blood lymphocyte isolation, VHH gene amplification, and phage/yeast display library construction (>10⁸ diversity).
Multi-round biopanning against immobilized antigen; ELISA-based primary screening of >1,000 clones.
Error-prone PCR and CDR-focused mutagenesis to achieve sub-nanomolar KD values for ELISA sensitivity.
Sandwich pair identification, LOD/LOQ determination, cross-reactivity panel, and stability profiling.
The global in vitro diagnostics (IVD) market is projected to exceed USD 130 billion by 2030. Nanobody-based ELISA kits are capturing an increasing share due to their superior lot-to-lot consistency, lower production cost, and compatibility with automated ELISA platforms. Leading diagnostic companies are actively transitioning from conventional monoclonal antibody pairs to nanobody sandwich pairs for infectious disease, oncology biomarker, and cardiac troponin assays.
Regulatory agencies worldwide are mandating stricter maximum residue limits (MRLs) for pesticides, mycotoxins, veterinary drug residues, and heavy metal chelators in food and water. Nanobodies, with their tolerance to organic solvents and extreme pH — conditions commonly encountered in food matrix extraction — are becoming the standard reagent for high-throughput ELISA screening in agricultural and environmental testing laboratories.
Regulatory compliance for biologics manufacturing (ICH Q6B, USP) requires sensitive ELISA-based quantification of host cell proteins (HCPs), residual protein A, and product-related impurities. Nanobodies are now preferred as ELISA capture/detection reagents for these critical quality attributes due to their programmable epitope coverage and compatibility with automated ELISA workstations in GMP environments.
Machine learning models (AlphaFold2, RoseTTAFold, ProteinMPNN) are revolutionizing in silico nanobody design for ELISA. Computational epitope prediction, CDR loop optimization, and in silico affinity maturation are dramatically reducing the time and cost of generating ELISA-ready nanobody leads. Alpha Lifetech integrates AI-assisted design into our experimental discovery pipeline, cutting campaign timelines by up to 40%.
The convergence of nanobody engineering with single-molecule array (Simoa) technology, electrochemical ELISA, and microfluidic chip-based ELISA platforms is enabling attomolar-level detection sensitivity. Nanobodies' small size and site-specific conjugation capability make them uniquely suited for high-density functionalization on ELISA sensor surfaces in these next-generation assay formats.
The global point-of-care testing (POCT) market is driving demand for ELISA-validated nanobodies that can be directly translated into lateral flow immunoassay (LFIA) strips. Nanobodies' exceptional stability under ambient conditions, compatibility with colloidal gold and latex bead conjugation, and small size enabling higher loading density on nitrocellulose membranes position them as the ideal bridge between laboratory ELISA and field-deployable POCT devices.
Anti-viral nanobodies targeting conserved epitopes on SARS-CoV-2 spike, influenza hemagglutinin, and HBsAg enable ultrasensitive sandwich ELISAs for early-stage infection detection with clinical sensitivity exceeding 99%.
Nanobody pairs against PSA, CEA, CA-125, and circulating tumor DNA-associated proteins enable multiplex ELISA panels for liquid biopsy applications, achieving detection limits in the femtomolar range in plasma.
Nanobodies against small-molecule haptens (β-lactam antibiotics, sulfonamides, chloramphenicol) enable competitive ELISA formats for food safety screening in milk, meat, and aquaculture products at sub-ppb sensitivity.
Anti-IL-6, anti-TNF-α, and anti-IFN-γ nanobody pairs deliver high-sensitivity sandwich ELISAs for cytokine profiling in autoimmune disease, CAR-T therapy monitoring, and sepsis management with minimal sample volume requirements.
Idiotype-specific nanobodies enable drug-tolerant ELISA formats for anti-drug antibody (ADA) detection and pharmacokinetic monitoring of biologic therapeutics including adalimumab, trastuzumab, and checkpoint inhibitors.
Hapten-specific nanobodies with engineered cross-reactivity profiles enable broad-spectrum competitive ELISAs for aflatoxin B1, ochratoxin A, and organophosphate pesticide detection in grain, feed, and processed food matrices.
From antigen design and camelid immunization to VHH library construction, high-throughput ELISA screening, affinity maturation, and GMP-grade production — Alpha Lifetech Inc. delivers fully validated nanobody ELISA pairs with complete characterization data packages. Our integrated technology platforms, experienced scientific team, and commitment to quality make us the preferred partner for IVD companies, academic research institutions, and biopharmaceutical organizations worldwide.
Alpha Lifetech Inc. was founded by a group of scientists with extensive experience in membrane protein production, nanobody discovery, monoclonal development, and other pharmaceutical pre-development services. Based on our several technology service platforms, Alpha Lifetech Inc. has launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, drug target antibodies and other related reagents. Whether you're working in the fields of immunology, cell biology, molecular biology, or any other scientific discipline, Alpha Lifetech's comprehensive range of research products will help you achieve accurate and reliable results. We pride ourselves on being able to offer a comprehensive set of high-quality products and services tailored to customer needs, which help advance the projects of scientific research institutions, academics, and enterprises in the life science industry.
Alpha Lifetech Inc. is committed to providing the highest level of customer services, competitive pricing, speedy delivery, and a comprehensive, cutting-edge product offering. Our sales and technical support staff are available to help you select the right products and service solutions. As a reliable supplier and partner, Alpha Lifetech Inc. always puts customers first. We cherish every opportunity to collaborate with worldwide customers in scientific exploration. Welcome to contact our technical support at any time.
Our platform utilizes phage and yeast display technology to develop different forms of antibodies: VHH single domain antibodies, Fab antibodies, and scFv antibodies, resulting in high affinity and high specificity antibodies optimized for ELISA capture and detection applications. Whether you require sandwich ELISA pairs, competitive ELISA haptens, or multiplex immunoassay reagents, our discovery pipeline delivers.
READ MORE
VHH Antibody Discovery Service
View Details
Fab Antibody Discovery Service
View Details
ScFv Antibody Discovery Service
View Details
Phage Display System
View Details
Phage Library Construction Service
View Details
Phage Display Screening Service
View DetailsThe aptamer platform provided by Alpha Lifetech includes two categories: aptamer synthesis platform, which mainly involves SELEX aptamer library synthesis service and aptamer development service, and aptamer screening platform including screening services based on SELEX technology for proteins, peptides, cells, small molecules, and other target molecules, as well as aptamer optimization and identification analysis services — all applicable to ELISA-format assay development.
READ MORE
Aptamer Synthesis Platform
View Details
Aptamer Screening Platform
View Details
Aptamer Optimization Service
View Details
Aptamer Analysis Service
View Details
Aptamer Research Service
View Details
Our monoclonal antibody development services include three technologies: phage display technology, single-B cell technology, and hybridoma cell technology, which produce monoclonal antibodies for different species — all applicable to ELISA pair development and sandwich assay construction for research and diagnostic applications.
READ MORE
Single B Cell Sorting Platform
View Details
Hybridoma Technology Platform
View Details
Phage Display Technology Platform
View Details
Mouse mAb Development Service
View Details
Rabbit mAb Development Service
View DetailsWe also provide a series of technical services related to antibody engineering, stable cell line construction, yeast display, protein interaction analysis, etc., laying the foundation for antibody development and ELISA assay optimization. These supporting technologies ensure that every nanobody delivered by Alpha Lifetech is fully characterized and ready for immediate integration into your ELISA workflow.
READ MORE
Stable Cell Line Construction Service
View Details
Animal Immunization Platform
View Details
Protein Interaction Service
View Details
Yeast Display Library Construction Service
View Details
Yeast Display Library Screening Service
View DetailsExceptional Nanobody discovery capabilities from Alpha Lifetech. Their team's dedication to customer satisfaction and scientific excellence is evident in every interaction. Grateful for their partnership and looking forward to future collaborations!
— Riley HarperQuality products! Our experience with Alpha Lifetech has been nothing short of outstanding. The nanobody ELISA pairs they delivered exceeded our sensitivity requirements for our diagnostic kit development.
— Stella GrantReliable, responsive, and results-driven — Alpha Lifetech. Their nanobody design pipeline for ELISA is truly best-in-class. We received fully validated sandwich pairs with comprehensive characterization data.
— Olivia WestSimply put, Alpha Lifetech delivers. Their dedication to customer satisfaction and quality service is unmatched, and we're grateful to have them as a trusted partner for our ELISA-based biomarker programs.
— Ava Mitchell
VHH Nanobody Discovery for ELISA
View Details
Fab Antibody ELISA Service
View Details
ScFv Antibody ELISA Service
View Details
Phage Display ELISA System
View Details
Single B Cell ELISA Sorting Platform
View Details
Hybridoma ELISA Technology Platform
View Details
ELISA Nanobody Affinity Maturation
View Details
Yeast Display ELISA Screening Service
View Details